Monday, 1 September 2008 - European Heart Journal

More documents

Recommendations

Info

$Heart failure with preserved ejection fraction - European Heart Journal$

304 Perspectives in heart failure treatment / <strong>Heart</strong> failure: peripheral mechanisms Afterload-lowering therapy significantly reduced BNP levels during the first 6hours (1336pg/ml [788-2302] initial vs 1136pg/ml [704-2273] 6hours, p=0.034) and continued to significantly decrease BNP levels every 6hours until 36hours. Overall, afterload-lowering therapy decreased BNP levels by 33% (p
P1973 Effect of ursodeoxycholic acid on peripheral blood flow, immune function & markers of neurohormonal activation in chronic heart failure: a randomised, placebo-controlled, double-blind cross-over study S. Von Haehling 1 ,E.A.Jankowska2 ,A.Vazir1 ,P.R.Kalra1 , A. Sandek3 , W. Doehner3 ,H.D.Volk3 , P.A. Poole-Wilson1 , S.D. Anker3 . 1National <strong>Heart</strong> & Lung Institute, Clinical Cardiology, London, United Kingdom; 2 3 Military Hospital, Wroclaw, Poland; Charite Medical School, Applied Cachexia Research, Dept. Cardiology, Berlin, Germany Background: Inflammation contributes to increased mortality and to the development of endothelial dysfunction in patients with chronic heart failure (CHF). Endotoxin, a bacterial cell wall component, which enters the circulation through the oedematous gut wall, could be the responsible trigger. We tested the hypothesis that ursodeoxycholic acid (UDCA), a bile acid that inhibits endotoxin absorption through the gut wall, would improve endothelial and immune function in CHF patients. Methods: In a placebo-controlled, double-blind, cross-overstudy, 16 male CHF patients (age 66±3y, 75% ischaemic aetiology, NYHA class 2.4±0.1, LVEF 31±2%[all 0.7). UDCA decreased WBC (6.9±0.4 vs 7.6±0.4,p=0.0075), absolute neutrophil (4.6±0.4 vs 5.1±0.4, p=0.025), and lymphocyte count (1.5±0.1 vs 1.7±0.1, p=0.013) compared to placebo. UDCA decreased plasma values of aspartate aminotransferase (AST, 19±2 vs22±1, p=0.025) and gamma-glutamyl transpeptidase (gGT, 29±3 vs37±6,p=0.0094) compared to placebo. Conclusions: UDCA administration is safe in patients with CHF. UDCA improves endothelial function, possibly by micell formation around endotoxin. Furthermore, UDCA improves liver function and decreases the number of neutrophils and lymphocytes in patients with CHF. P1974 The impact of irbesartan on impaired insulin sensitivity in chronic heart failure - results from a placebo-controlled, double blinded, randomized proof of concept-trial W. Doehner1 , T. Karhausen1 , C. Kennecke 1 , J. Todorovic 1 , M. Rauchhaus1 , A. Sandek1 , M. Lainscak2 , S. Von Haehling1 , S.D. Anker1 . 1Charite Medical School Campus Virchow Hosp., Applied Cachexia Research, Dpt of Cardiology, Berlin, Germany; 2General Hospital Murska Sobota, Internal Medicine, Murska Sobota, Slovenia Background: Impaired insulin sensitivity (Si) is common in chronic heart failure (CHF), contributes to symptomatic status and independently predicts prognosis. The angiotensin II-receptor antagonist irbesartan (ARA) has been observed to improve insulin sensitivity via peroxisome proliferator-activated receptor gamma (PPAR gamma). Whether this effect can be detected in the clinical setting of chronic heart failure has not been investigated. Methods: In a placebo-controlled, double-blinded, 2:1-randomized study design we investigated 36 ambulatory patients with stable ischaemic CHF (age 63±9y, BMI 28.2±3.9kg/m 2 , peakVO2 16.6±4.8mL/kg/min all mean ±SD). All patients were free of diabetes and without antidiabetic therapy. Irbesartan or placebo was given on top of standard optimum CHF therapy including ACE inhibitor (target dose 300mg/d) for 16 weeks including a 4-week up-titration period. Si (primary endpoint) was assessed at baseline and after therapy using the minimal modelling technique from glucose and insulin profiles of a frequently sampled intravenous glucose tolerance test. Results: At baseline both groups were similar for age, NYHA class, peak VO2, BMI, body composition (DEXA scan), and main clinical characteristics. Si was 2.51±1.58 min-1.μU.mL-1.104 in the study population, which is 30% lower than in healthy controls of similar age (P
Page 1 and 2: Monday, 1 September 2008 Downloaded
Page 3 and 4: CAN WE PREDICT ATRIAL FIBRILLATION?
Page 5 and 6: Thromboembolic risks and therapeuti
Page 7 and 8: Healthy bone marrow for a healthy h
Page 9 and 10: NEW PROGNOSTIC MARKERS IN ACUTE CAR
Page 11 and 12: CI 0.2-1.6, p=0.32) after epinephri
Page 13 and 14: Risk assessment: strengths and weak
Page 15 and 16: Prognosis in heart failure: surveys
Page 17 and 18: Restenosis: is there an alternative
Page 19 and 20: Confonding factors influencing outc
Page 21 and 22: New vessels and changed vessels: an
Page 23 and 24: (n=574) served as the cohort where
Page 25 and 26: Using Cox’s proportional hazards
Page 27 and 28: hibitory response, or in pts with p
Page 29 and 30: Multimodality imaging of coronary h
Page 31 and 32: Conclusions: EVH is a strong indepe
Page 33 and 34: any antiarrhythmic drug (AAD), Grou
Page 35 and 36: oxidases decreased O2- by 16±3.1%
Page 37 and 38: Fig. 1. Five types of merge errors.
Page 39 and 40: manent AF were studied. The number
Page 41 and 42: P1933 Left atrial appendage dominan
Page 43 and 44: hydrolysable, it would dissipate be
Page 45 and 46: P1949 A first-in-human clinical tri
Page 47 and 48: P1957 Electrophysiological effects
Page 49: for the population of Tayside, Scot
Page 53 and 54: =0.31, p=0.0003) and QUICKI (r=0.29
Page 55 and 56: P1989 Hormonal mechanisms of cachex
Page 57 and 58: or more of the following ECG change
Page 59 and 60: P2004 Association between cardiovas
Page 61 and 62: P2012 Correlations between the degr
Page 63 and 64: disease. Familial study was recomen
Page 65 and 66: P2027 MRI for the detection of rest
Page 67 and 68: P2035 Oxidized low density lipoprot
Page 69 and 70: P2042 Persistent under representati
Page 71 and 72: P2049 Addition of B-type natriureti
Page 73 and 74: P2058 Genetic variation in CYP2C19
Page 75 and 76: p=0.003). Minor bleeding was also l
Page 77 and 78: Avidin, a protein found in hen eggs
Page 79 and 80: flow, and
Page 81 and 82: (PCWP) were recorded. In 16 patient
Page 83 and 84: Methods: A prospective, consecutive
Page 85 and 86: over paclitaxel-eluting stent (PES)
Page 87 and 88: which proved to be safe and effecti
Page 89 and 90: Comparison of neointimal growth amo
Page 91 and 92: patients between October 2006 and J
Page 93 and 94: P2139 Inverse relation of baseline
Page 95 and 96: tive. We sought to determine the ef
Page 97 and 98: P2155 A very high prevalence of low
Page 99 and 100: P2163 The influence of estradiol on
Page 101 and 102:
2nd year of follow-up, respectively
Page 103 and 104:
P2179 Symptoms of atrial fibrillati
Page 105 and 106:
P2187 The relationships of ambulato
Page 107 and 108:
tension (WCHT) to vascular damage i
Page 109 and 110:
in the postero- and midseptal regio
Page 111 and 112:
elevation myocardial infarction (AM
Page 113 and 114:
assigned to receive either unselect
Page 115 and 116:
was injected. Left ventricular func
Page 117 and 118:
of MACE in patients with LGE and de
Page 119 and 120:
P2243 Blood oxygenation level-depen
Page 121 and 122:
P2250 Prognostic value of revascula
Page 123 and 124:
needed to achieve 90% of age-predic
Page 125 and 126:
presence/absence of VIVC assessed u
Page 127 and 128:
2341 Telemonitoring in an elderly,
Page 129 and 130:
Heart failure with preserved systol
Page 131 and 132:
the most dilated, LA mostly influen
Page 133 and 134:
Conclusion: In patients with stable
Page 135 and 136:
2388 Magnitude of glycaemia variati
Page 137 and 138:
patients with RV > 30 ml this corre
Page 139 and 140:
BIOMARKERS: NEW KIDS ON THE BLOCK 2
Page 141 and 142:
the importance of calling the emerg
Page 143 and 144:
Sudden death, devices and public aw
Page 145 and 146:
Bone marrow progenitors: filling th
Page 147 and 148:
2566 Esophageal capsule endoscopy i
Page 149 and 150:
(7.0%) patients receiving aliskiren
Page 151 and 152:
P2600 Final aggregation response is
Page 153 and 154:
Results: Female patients (27.7%) we
Page 155 and 156:
with atrial fibrillation (AF) under
Page 157 and 158:
e feasible and safe. This approach
Page 159 and 160:
coagulant therapy (P=0.038; OR=2.42
Page 161 and 162:
ison between responders and nonresp
Page 163 and 164:
Table 1. Systolic, diastolic and dy
Page 165 and 166:
Syncope and cardiac pacing: miscell
Page 167 and 168:
their downstream effector, myosin h
Page 169 and 170:
Understanding determinants of hemod
Page 171 and 172:
the abundance of profibrotic CCN2 p
Page 173 and 174:
parison with IL-8 as well as the ex
Page 175 and 176:
and EF (-0.5%) which significantly
Page 177 and 178:
of effects on systemic BP and cardi
Page 179 and 180:
Conclusion: Compared to previously
Page 181 and 182:
P2723 Differential virus-associated
Page 183 and 184:
Methods: During 2007, 10 patients (
Page 185 and 186:
cardiomyocyte apoptosis was highest
Page 187 and 188:
higher for NT-proBNP (area under th
Page 189 and 190:
or higher) in 85 patients (4.2%). M
Page 191 and 192:
teria as a final Thrombolysis In My
Page 193 and 194:
cantly correlated to in-hospital de
Page 195 and 196:
nosis in patients with myocardial i
Page 197 and 198:
lesion classification, stent type u
Page 199 and 200:
Prognosis in ST-elevation myocardia
Page 201 and 202:
P2802 In-hospital and long-term mor
Page 203 and 204:
P2810 Long-term clinical results fo
Page 205 and 206:
Percutaneous coronary intervention;
Page 207 and 208:
vessels (DES 16.7%, BMS 6.7%, p=0.0
Page 209 and 210:
patients receiving a DES and the ra
Page 211 and 212:
Results: The two groups had similar
Page 213 and 214:
among their non-DM counterparts (HR
Page 215 and 216:
tigated the long-term consequences
Page 217 and 218:
culogenesis. Reduction of VPC and E
Page 219 and 220:
y echo-tracking technique calibrate
Page 221 and 222:
P2885 Statins are effective in redu
Page 223 and 224:
Conclusions: The patient-centred he
Page 225 and 226:
P2900 Should left ventricular hyper
Page 227 and 228:
P2908 Telmisartan up-regulates the
Page 229 and 230:
important sex-based differences in
Page 231 and 232:
Hypertension: regional and ethnic p
Page 233 and 234:
whether the selective mineralocorti
Page 235 and 236:
THE ENDOTHELIUM: AT THE HEART OF VA
Page 237 and 238:
P2951 Reproducibility of endothelia
Page 239 and 240:
P2959 Brachial flow-mediated dilati
Page 241 and 242:
P2966 Detection of late enhancement
Page 243 and 244:
tissue as an enhanced area. On the
Page 245 and 246:
dial dysfunction is critical for th
Page 247 and 248:
for testing the load dependence. Th
Page 249:
diastolic velocity (-12.3±4.9 vs -
show all

Monday, 1 September 2008 - European Heart Journal

Create successful ePaper yourself

Delete template?

Save as template?